Literature DB >> 23817425

The encephalitogenic, human myelin oligodendrocyte glycoprotein-induced antibody repertoire is directed toward multiple epitopes in C57BL/6-immunized mice.

Pankaj Bansal1, Tarique Khan, Uta Bussmeyer, Dilip K Challa, Rafal Swiercz, Ramraj Velmurugan, Raimund J Ober, E Sally Ward.   

Abstract

Although Abs specific for myelin oligodendrocyte glycoprotein (MOG) have been detected in patients with multiple sclerosis (MS), their contribution to pathogenesis remains poorly understood. Immunization of C57BL/6 mice with recombinant human MOG (hMOG) results in experimental autoimmune encephalomyelitis involving MOG-specific, demyelinating Abs. This model is therefore informative for understanding anti-MOG humoral responses in MS. In the current study, we have characterized the hMOG-specific Ab repertoire in immunized C57BL/6 mice using both in vitro and in vivo approaches. We demonstrate that hMOG-specific mAbs are not focused on one specific region of MOG, but instead target multiple epitopes. Encephalitogenicity of the mAbs, assessed by the ability of the mAbs to exacerbate experimental autoimmune encephalomyelitis in mice, correlates with the activity of the mAbs in binding to CNS tissue sections, but not with other in vitro assays. The targeting of different MOG epitopes by encephalitogenic Abs has implications for disease pathogenesis, because it could result in MOG cross linking on oligodendrocytes and/or immune complex formation. These studies reveal several novel features concerning pathogenic, humoral responses that may have relevance to human MS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23817425     DOI: 10.4049/jimmunol.1300019

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis.

Authors:  Dilip K Challa; Uta Bussmeyer; Tarique Khan; Héctor P Montoyo; Pankaj Bansal; Raimund J Ober; E Sally Ward
Journal:  MAbs       Date:  2013-06-19       Impact factor: 5.857

2.  Effect of Bushen Yisui Capsule () on oligodendrocyte lineage genes 1 and 2 in mice with experimental autoimmune encephalomyelitis.

Authors:  Tao Yang; Qi Zheng; Hui Zhao; Qiu-Xia Zhang; Ming Li; Fang Qi; Kang-Ning Li; Ling Fang; Lei Wang; Yong-Ping Fan
Journal:  Chin J Integr Med       Date:  2016-02-26       Impact factor: 1.978

Review 3.  Targeting FcRn for therapy: from live cell imaging to in vivo studies in mice.

Authors:  E Sally Ward; Ramraj Velmurugan; Raimund J Ober
Journal:  Immunol Lett       Date:  2014-02-23       Impact factor: 3.685

4.  Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms.

Authors:  Ding Chen; Monica Blazek; Sara Ireland; Sterling Ortega; Xiangmei Kong; Anouk Meeuwissen; Ann Stowe; Laura Carter; Yue Wang; Ronald Herbst; Nancy L Monson
Journal:  J Immunol       Date:  2014-10-03       Impact factor: 5.422

5.  Humoral response in experimental autoimmune encephalomyelitis targets neural precursor cells in the central nervous system of naive rodents.

Authors:  Evangelia Kesidou; Olga Touloumi; Roza Lagoudaki; Evangelia Nousiopoulou; Paschalis Theotokis; Kyriaki-Nepheli Poulatsidou; Marina Boziki; Evangelia Kofidou; Nickoleta Delivanoglou; Fani Minti; Georgios Hadjigeorgiou; Nikolaos Grigoriadis; Constantina Simeonidou
Journal:  J Neuroinflammation       Date:  2017-11-21       Impact factor: 8.322

6.  Engineered clearing agents for the selective depletion of antigen-specific antibodies.

Authors:  Siva Charan Devanaboyina; Priyanka Khare; Dilip K Challa; Raimund J Ober; E Sally Ward
Journal:  Nat Commun       Date:  2017-05-31       Impact factor: 14.919

7.  Selective Depletion of Antigen-Specific Antibodies for the Treatment of Demyelinating Disease.

Authors:  Wei Sun; Priyanka Khare; Xiaoli Wang; Dilip K Challa; Benjamin M Greenberg; Raimund J Ober; E Sally Ward
Journal:  Mol Ther       Date:  2020-11-17       Impact factor: 11.454

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.